Emergent Travel Health have decided to temporarily discontinue the manufacture and distribution of Vaxchora® (cholera vaccine, live, oral) and Vivotif® (typhoid vaccine live oral Ty21a) in the US due to a significant reduction in international travel due to the COVID-19 pandemic.
Vaxchora is an oral vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup 01 in adults 18 to 64 years of age traveling to cholera-affected areas. Vivotif is an oral live attenuated vaccine indicated for immunization against disease caused by Salmonella typhi in patients 6 years of age and older.
The decision was made to temporarily discontinue US distribution after an assessment of data determined a lengthy recovery period for international travel. The Company will resume the manufacture and distribution of Vaxchora and Vivotif in the US once global travel resumes; the estimated duration of this interruption is expected to be 1 year.
- CBER-regulated products: current shortages. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-current-shortages. Accessed May 26, 2021.
- Temporary distribution suspension notification. Emergent Biosolutions Inc. https://emergenttravelhealth.com/fda-notice. Accessed May 26, 2021.